Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study
Panpan Zhang(Peking University), Ming Lü(Peking University), Xiaolu Tao(Shanghai Harbour Engineering Design & Research Institute), Di Yang(Shanghai Harbour Engineering Design & Research Institute), Ruixuan Luo(Shanghai Harbour Engineering Design & Research Institute), Lijie Song(Shanghai Architectural Design & Research Institute), Jianwei Yang(Fujian Provincial Cancer Hospital), Yanxia He(Shanghai Harbour Engineering Design & Research Institute), Lin Shen(Peking University), Fei Zheng(Shanghai Harbour Engineering Design & Research Institute), Nan Cao(Shanghai Harbour Engineering Design & Research Institute), Feng Li(Shanghai Harbour Engineering Design & Research Institute), Kai Chen(Chinese Academy of Sciences)
Cited by 3
Related Papers
An Analysis of Human MicroRNA and Disease Associations
|PLoS ONE|2008|912
Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy
|Cancer Science|2016|184
Extracellular vesicles derived from hypoxia-preconditioned olfactory mucosa mesenchymal stem cells enhance angiogenesis via miR-612
|Journal of Nanobiotechnology|2021|173
Ti<sub>n+1</sub>C<sub>n</sub> MXenes with fully saturated and thermally stable Cl terminations
|Nanoscale Advances|2019|130